TheEdgeResearch
Home / Stocks / BDSX

Biodesix, Inc. (BDSX)

NASDAQ Healthcare Medical - Diagnostics & Research
$24.92 ▲ +2.51%
Market Cap
$202.9M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.56
52-Wk Range
5.26-25.52
CEO
Scott Hutton
Country
US
Currency
USD

Biodesix, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Louisville, CO, US. The stock last traded at $24.92, up 2.51% on the session, giving a market capitalisation of $202.9M. On trailing twelve-month figures it carries a trailing P/E of -7.86, a net margin of -27.0%. Its beta of 0.56 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-7.86
Price / Sales
1.97
Price / Book
28.06
EV / EBITDA
-17.13
Gross margin
82.5%
Operating margin
-20.0%
Net margin
-27.0%
Return on equity
Debt / equity
7.85
Current ratio
2.85
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
334
IPO date
2020-10-28
Headquarters
Louisville, CO, US
About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Comparable companies

Biodesix, Inc. is most often compared with the following Healthcare names:

ALGSINMBMRSNNOTVOKURPDSBSKYEVNRXWGRXXLO
More research on BDSX
BDSX technical analysis BDSX TheEdge Score Compare against peers
Open full interactive analysis & DCF →